US2008118505A1PendingUtilityA1
Reagents and treatment methods for autoimmune diseases
Est. expiryFeb 21, 2022(expired)· nominal 20-yr term from priority
Inventors:Thomas F. Tedder
A61P 35/00A61P 9/00A61P 5/16A61P 37/02A61P 9/08A61P 7/02A61P 3/10A61P 37/04A61P 7/04A61P 9/10A61P 7/00A61P 5/14A61P 7/06A61P 37/08A61P 35/02A61P 37/06A61P 37/00A61P 5/00A61P 27/02A61P 25/00A61P 29/00C07K 2317/73A61P 19/02A61K 39/39533C07K 2317/56A61P 1/04A61P 19/00A61P 13/12A61P 21/00A61P 17/06C07K 16/2803A61P 1/00A61P 13/02C07K 2317/76A61P 21/04A61P 19/04A61K 2039/505A61P 17/02A61P 17/00A61K 39/395C07K 16/28C12N 15/11
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).
Claims
exact text as granted — not AI-modified1 - 38 . (canceled)
39 . A humanized monoclonal antibody that specifically binds to human CD22 comprising a heavy chain with variable heavy (VH) complementarity determining regions (CDRs) and a light chain with variable light (VL) CDRs, wherein said antibody specifically binds to the first two Ig-like domains or to an epitope associated with the first two Ig-like domains of native human CD22.
40 . A humanized monoclonal antibody that specifically binds to human CD22 comprising a heavy chain with VH CDRs and a light chain with VL CDRs, wherein said antibody binds essentially the same epitope as an antibody selected from the group consisting of HB22-7, HB22-23, or HB22-33.
41 . The humanized monoclonal antibody of claim 39 or 40 , wherein the heavy chain of said antibody further comprises the amino acid sequence of the VH CDR1, VH CDR2, and VH CDR3 of HB22-7.
42 . The humanized monoclonal antibody of claim 39 or 40 , wherein the light chain of said antibody further comprises the amino acid sequence of the VL CDR1, VL CDR2, and VL CDR3 of HB22-7.
43 . The humanized monoclonal antibody of claim 39 or 40 , wherein said antibody further comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:34 (DYGVN), a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 40 (IIWGDGRTDYNSALKS), and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:46 (APGNRA).
44 . The humanized monoclonal antibody of claim 39 or 40 , wherein said antibody further comprises a VL CDR1 comprising the amino acid sequence KASQSVTNDVA (SEQ ID NO: 51), a VL CDR2 comprising the amino acid sequence YASNRYT (SEQ ID NO: 57), and a VL CDR3 comprising the amino acid sequence QQDYRSPWT (SEQ ID NO: 63).
45 . The humanized monoclonal antibody of claim 44 , wherein said antibody further comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:34 (DYGVN), a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 40 (IIWGDG RTDYNSALKS), and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:46 (APGNRA).
46 . A humanized monoclonal antibody that specifically binds to human CD22 comprising a heavy chain with VH CDRs and a light chain with VL CDRs, wherein said antibody further comprises:
(a) a VH CDR1 comprising an amino acid sequence selected from the following:
DYTMN,
(SEQ ID NO: 32)
GYYMH,
(SEQ ID NO: 33)
DYGVN,
(SEQ ID NO: 34)
GYYWN,
(SEQ ID NO: 35)
DYYMN,
(SEQ ID NO: 36)
or
YYWMN;
(SEQ ID NO: 37)
(b) a VH CDR2 comprising an amino acid sequence selected from the following:
LLHPFNGGTSYNQKFKG,
(SEQ ID NO: 38)
AVNPNTAGLTYNQRFKD,
(SEQ ID NO: 39)
IIWGDGRTDYNSALKS,
(SEQ ID NO: 40)
YIRYDGSNNYNPSLKN,
(SEQ ID NO: 41)
FIKNKFNGYTTEYNTSVKG,
(SEQ ID NO: 42)
or
AEIRLKSNNYATHYAESVKG;
(SEQ ID NO: 43)
and
(c) a VH CDR3 comprising an amino acid sequence selected from the following:
GTGRNYA,
(SEQ ID NO: 44)
VDYDDYGYWF,
(SEQ ID NO: 45)
APGNRA,
(SEQ ID NO: 46)
GGITVA,
(SEQ ID NO: 47)
GLGRSYA,
(SEQ ID NO: 48)
or
YDGSSR.
(SEQ ID NO: 49)
47 . A humanized monoclonal antibody that specifically binds to human CD22 comprising a heavy chain with VH CDRs and a light chain with VL CDRs, wherein said antibody further comprises:
(a) a VL CDR1 comprising an amino acid sequence selected from the following:
KASQTVTNDLA,
(SEQ ID NO: 50)
KASQSVTNDVA,
(SEQ ID NO: 51)
KASQSVTNDVT,
(SEQ ID NO: 52)
KASQSVSNDVA,
(SEQ ID NO: 53)
RSSQSLVHSNGNTYLH,
(SEQ ID NO: 54)
or
KASENVVTYVS;
(SEQ ID NO: 55)
(b) a VL CDR2 comprising an amino acid sequence selected from the following:
YASNRYT,
(SEQ ID NO: 56)
YASNRYT,
(SEQ ID NO: 57)
FASNRYT,
(SEQ ID NO: 58)
YASKRYT,
(SEQ ID NO: 59)
KVSNRFS,
(SEQ ID NO: 60)
or
GASNRYT;
(SEQ ID NO: 61)
and
(c) a VL CDR3 comprising an amino acid sequence selected from the following:
QQDYSSPLT,
(SEQ ID NO: 62)
QQDYRSPWT,
(SEQ ID NO: 63)
QQDYSSPLT,
(SEQ ID NO: 64)
QQDHSYPWT,
(SEQ ID NO: 65)
SQSTHVPYT,
(SEQ ID NO: 66)
or
GQGYSYPYT.
(SEQ ID NO: 67)
48 . The humanized monoclonal antibody of claim 47 , wherein said antibody further comprises:
(a) a VH CDR1 comprising an amino acid sequence selected from the following:
DYTMN,
(SEQ ID NO: 32)
GYYMH,
(SEQ ID NO: 33)
DYGVN,
(SEQ ID NO: 34)
GYYWN,
(SEQ ID NO: 35)
DYYMN,
(SEQ ID NO: 36)
or
YYWMN;
(SEQ ID NO: 37)
(b) a VH CDR2 comprising an amino acid sequence selected from the following:
LLHPFNGGTSYNQKFKG,
(SEQ ID NO: 38)
AVNPNTAGLTYNQRFKD,
(SEQ ID NO: 39)
IIWGDGRTDYNSALKS,
(SEQ ID NO: 40)
YIRYDGSNNYNPSLKN,
(SEQ ID NO: 41)
FIKNKFNGYTTEYNTSVKG,
(SEQ ID NO: 42)
or
AEIRLKSNNYATHYAESVKG;
(SEQ ID NO: 43)
and
(c) a VH CDR3 comprising an amino acid sequence selected from the following:
GTGRNYA,
(SEQ ID NO: 44)
VDYDDYGYWF,
(SEQ ID NO: 45)
APGNRA,
(SEQ ID NO: 46)
GGITVA,
(SEQ ID NO: 47)
GLGRSYA,
(SEQ ID NO: 48)
or
YDGSSR.
(SEQ ID NO: 49)
49 . A pharmaceutical composition comprising a humanized anti-CD22 monoclonal antibody of claim 39 or 40 , in a pharmaceutically-acceptable carrier.
50 . A method of treating a human diagnosed with an autoimmune disease or disorder, comprising administering to said human an effective amount of the humanized monoclonal antibody of claim 39 or 40 .
51 . The method of claim 50 , wherein said treatment is unaccompanied by any other treatment for the autoimmune disease.
52 . The method of claim 50 , wherein said antibody is a fragment of a complete antibody.
53 . The method of claim 50 , wherein said antibody is a bispecific antibody.
54 . The method of claim 50 , wherein said antibody is administered intravenously.Join the waitlist — get patent alerts
Track US2008118505A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.